Thermo Fisher Scientific Inc. (NYSE:TMO) agreed to pay an unspecified amount for Finnish polymerase chain reaction equipment maker Finnzyme, in a bid to bolster one of its own recent PCR assay offerings.
The Waltham, Mass.-based lab equipment maker said it inked the deal to acquire Espoo, Finland-based Finnzyme because that company’s proprietary DNA polymerases, Phire and Phusion, complement its own Solaris line of real-time quantitative PCR assays. The deal is expected to close during the first quarter.